Study
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
| Study ID | Alternative Stable ID | Type |
|---|---|---|
| EGAS00001005013 | Other |
Study Description
Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients, based on their significant overall survival (OS) benefit. Using transcriptomic analysis of 891 NSCLC tumors from patients treated with either the PD-L1 inhibitor atezolizumab or chemotherapy from two large randomized clinical trials, we found a significant B cell association with extended OS with PD-L1 blockade, independent of CD8+ T cell signals. We then derived gene signatures corresponding to the dominant B cell subsets present in NSCLC from single-cell RNA-seq data. Importantly, we found increased plasma cell signatures to be predictive of OS in patients treated with atezolizumab, but not chemotherapy. B cells were also associated with the presence of tertiary lymphoid structures and organized lymphoid aggregates. Our results suggest an important contribution of B and plasma cells to PD-L1 blockade efficacy in NSCLC.
Study Datasets 10 datasets.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD00001007703 |
This dataset includes full tumor transcriptomes from 891 advanced NSCLC tumors. These data originate from pre-treatment samples from two large randomized clinical trials for second-line non-small cell lung cancer (POPLAR and OAK). The patients in these trials were treated with either the PD-L1 inhibitor atezolizumab or chemotherapy.
|
unspecified | 891 |
| EGAD00001008390 |
This dataset contains log2(TPM + 1) for 192 tumor samples profiled by RNA-seq for the entire transcriptome for samples originating from POPLAR (GO28753).
|
N/A | |
| EGAD00001008391 |
This dataset contains log2(TPM + 1) for 699 tumor samples profiled by RNA-seq for the entire transcriptome for samples originating from OAK (GO28915).
|
N/A | |
| EGAD00001008548 |
Relevant clinical data for POPLAR including treatment arm, histology, overall survival, progression-free survival, and best confirmed overall response.
|
N/A | |
| EGAD00001008549 |
Relevant clinical data for OAK including treatment arm, histology, overall survival, progression-free survival, and best confirmed overall response.
|
N/A | |
| EGAD00001008550 |
Additional relevant biomarker data for OAK including PD-L1 tumor cell IHC by the 22C3 assay, tumor mutational burden status, and STK11, KEAP1, and EGFR mutation status.
|
N/A | |
| EGAD00001008628 |
This dataset contains counts for 699 tumor samples profiled by RNA-seq for the entire transcriptome for samples originating from OAK (GO28915).
|
N/A | |
| EGAD00001008629 |
This dataset contains counts per million for 699 tumor samples profiled by RNA-seq for the entire transcriptome for samples originating from OAK (GO28915).
|
N/A | |
| EGAD00001008630 |
This dataset contains counts for 192 tumor samples profiled by RNA-seq for the entire transcriptome for samples originating from POPLAR (GO28753).
|
N/A | |
| EGAD00001008631 |
This dataset contains counts per million for 192 tumor samples profiled by RNA-seq for the entire transcriptome for samples originating from POPLAR (GO28753).
|
N/A |
Who archives the data?
